Small Molecules Vs Car T In Cll is an active area of clinical research and therapeutic development covered by The Life Science Feed. Our editorial team tracks the latest clinical trials, treatment guidelines, regulatory updates, and scientific advances relevant to Small Molecules Vs Car T In Cll. Browse the latest articles below for in-depth analysis and evidence-based clinical insights.
What Is CAR-T Cell Therapy? Mechanism, Approved Indications, and Key Evidence
CAR-T cell therapy reprogrammes a patient's own T cells to seek and destroy cancer cells. Here is what clinicians need to know about how it works, which cancers it is approved for, and what the evidence shows.
What Is an SGLT2 Inhibitor? Mechanism, Indications, and Evidence
SGLT2 inhibitors block renal glucose reabsorption to lower blood sugar and protect the heart and kidneys. A clinical primer on mechanism, approved agents, key trial evidence, and safety.
Infrared saunas for workout recovery: still more hype than help?
Evidence for infrared saunas improving workout recovery remains limited and inconsistent, with studies showing mixed results on muscle soreness and performance.
Fake medicines: How to spot substandard drugs and protect your patients
One in ten medicines globally is estimated to be fake or substandard, posing significant health risks. Clinicians must verify drug sources and educate patients.
Chronic Migraine: Is the Gut-Brain Axis the Missing Link?
Chronic migraine frequently co-occurs with gastrointestinal issues, suggesting a gut-brain axis involvement through dysbiosis and inflammation.
Why lifestyle advice alone still dominates obesity searches
Despite advances in pharmacotherapy, Google searches for obesity management remain heavily skewed towards lifestyle interventions, indicating a persistent public perception.
Why clinician wellness is not a luxury, but a bedrock of patient care
Clinician well-being directly impacts patient outcomes, with recent research emphasizing holistic approaches to care and engagement.
Jideytro offers new hope for ROS1-positive NSCLC after prior therapy
The FDA approved Jideytro for previously treated ROS1-positive non-small cell lung cancer, providing a new option for this rare subtype.
Does dupilumab increase lymphoma risk in eczema patients?
Dupilumab, a common eczema treatment, has raised questions about its potential link to lymphoma. Data suggests no increased risk, but vigilance remains key.